Rethinking Genomic Access in Pediatric Care
GeneDx recently released data from a multi-year partnership with Seattle Children’s showing that rapid genome sequencing provides high diagnostic value outside the intensive care unit. The study, published in the journal Genetics in Medicine, analyzed more than 1,000 pediatric patients admitted to various hospital departments over three and a half years. While intensive care units have historically served as the primary setting for this testing, the data confirms that patients in general wards also benefit significantly from early genomic insights. The overall diagnostic yield for the cohort reached 35 percent.
Dr. Tara L. Wenger, a lead researcher on the study, noted that the medical field must reconsider which patients qualify for such testing. She stated that the benefits are not restricted to the NICU, PICU, or CICU. Many children across various hospital wards who face long and unresolved clinical problems gain clarity through these genetic tests. This findings shift the traditional focus of genomic medicine, moving it away from only the most critical emergency cases.
Higher Diagnostic Yields Outside the ICU
The research revealed surprising outcomes for patients in non-critical care settings. These wards recorded a 43 percent diagnostic yield, which outperformed many ICU-specific benchmarks. Children hospitalized for faltering growth saw a particularly high yield of 63 percent. In this specific group, researchers found 37 distinct genetic diagnoses among 36 patients, including several cases involving dual diagnoses. These results highlight a significant gap in current pediatric triage practices.
Dr. Alexandra C. Keefe, a clinical genetics physician at the hospital, highlighted the specific impact on children with growth issues. She explained that these patients were rarely viewed as primary candidates for rapid genomic sequencing until now. The data suggests that many children in non-critical settings possess underlying genetic conditions that remain undetected or are diagnosed far too late. By finding these answers during a hospital stay, doctors can update clinical management plans and improve long-term outcomes for families.
Equity and Future Implications for Hospitals
Beyond clinical results, the study identified improvements in healthcare equity. By moving rapid genome sequencing to a hospital-wide model, the researchers observed a reduction in outpatient wait times. This approach also removed race-based disparities in access to testing that had persisted under the previous ICU-limited model. The findings indicate that the historical barrier to broader testing was not just a lack of clinical suspicion, but also a flaw in the referral system itself.
This study adds to a growing body of work from GeneDx and Seattle Children’s. The partners previously published findings in The Journal of Pediatrics in June 2025 regarding the use of rapid sequencing as a first-tier test for non-critical pediatric inpatients. As a Maryland-based firm, GeneDx has spent 25 years in the field and claims to have diagnosed more than 4,800 genetic diseases to date. Their work provides a practical blueprint for other hospitals looking to integrate precision medicine into their standard inpatient workflows.
Dr. Linda Genen, the Chief Medical Officer at GeneDx, emphasized the scalability of this model. She suggested that by expanding access to testing in general wards, health systems can reduce bottlenecks in specialty care departments. This transition allows for a more equitable approach to pediatric diagnostics. As hospitals evaluate their internal standards, this data provides the necessary evidence to move genomic testing closer to the front door of inpatient care.